Health Catalyst (HCAT) 2024 Wells Fargo Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
2024 Wells Fargo Healthcare Conference summary
22 Jan, 2026Market and business environment
Operating environment has improved since late 2023, with end market health rebounding and client engagement returning to pre-pandemic levels.
Record new client wins in the first half of the year, surpassing all of last year, driven by improved market conditions and new platform offerings.
Updated guidance for new logo adds to the low twenties, marking the best year in company history for new clients.
Confidence in returning to double-digit top-line growth and 50%+ EBITDA growth in 2025, supported by a robust pipeline.
Current valuation reflects low growth, but management expects a re-rating as growth accelerates.
Product and technology strategy
Launched Ignite, a modular, flexible data platform, replacing the heavier, more expensive DOS platform.
Ignite leverages cross-industry tech (Snowflake, Databricks, Microsoft), enabling easier integration and future-proofing for AI and other innovations.
Modular approach lowers barriers for client adoption, shortens sales cycles, and increases cross-sell opportunities.
Cross-sell conversion rates have doubled with Ignite, and migration of 120 DOS customers to Ignite is on track for completion within three years.
All new customers are onboarded directly to Ignite, with dedicated migration teams and offshore support to improve efficiency.
Financial performance and outlook
Ignite platform delivers around 70% gross margin, compared to 60% for DOS; applications run at 80%+ gross margin.
Company-wide technology gross margin expected to rise into the 70s as Ignite adoption increases.
R&D and operating expenses are declining as Ignite investment winds down, with further leverage from offshore resources.
Non-recurring, project-based professional services are outperforming, contributing 3-4 points of existing client expansion growth.
Four-year outlook targets $500M top-line revenue and $100M EBITDA, with 10-15% annual revenue growth and 40%+ bottom-line growth.
Latest events from Health Catalyst
- 2025 revenue rose 1% to $311.1M, but net loss deepened on large impairment charges.HCAT
Q4 202512 Mar 2026 - Q2 revenue up 4% to $75.9M, EBITDA rose, and net loss narrowed on strong bookings.HCAT
Q2 20242 Feb 2026 - Q3 revenue up 3% to $76.4M, net loss narrows, and 2024 outlook raised for growth.HCAT
Q3 202416 Jan 2026 - Pre-pandemic demand, Ignite-driven growth, and margin expansion set up a return to double-digit growth.HCAT
7th Annual Evercore ISI HealthCONx Conference11 Jan 2026 - Double-digit growth and margin expansion driven by AI, platform migration, and strategic M&A.HCAT
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Tripled revenue, tech focus, and AI-driven efficiency set up 40% annual EBITDA growth.HCAT
Raymond James & Associates’ 46th Annual Institutional Investors Conference26 Dec 2025 - 2025 outlook targets $335M revenue, 13% tech growth, and 40 new platform clients.HCAT
Q4 20242 Dec 2025 - Board seeks approval for director elections, auditor, executive pay, and board declassification.HCAT
Proxy Filing1 Dec 2025 - Board elections, auditor ratification, and executive pay up for vote; strong governance and ESG focus.HCAT
Proxy Filing1 Dec 2025